Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 315

1.

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane.

Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J.

J Clin Oncol. 2015 Jan 20. pii: JCO.2013.52.4892. [Epub ahead of print]

PMID:
25605862
[PubMed - as supplied by publisher]
2.

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A.

Breast Cancer Res Treat. 2015 Jan;149(1):313. doi: 10.1007/s10549-014-3245-7. No abstract available.

PMID:
25573650
[PubMed - in process]
3.

Case Report: Mammary and rectal metastases from an ovarian cancer: report of two cases and review of literature.

Amzerin M, Garcia C, Stanciu C, Veys I, Awada A, Errihani H, Gombos A.

Version 2. F1000Res. 2014 Oct 28 [revised 2014 Dec 9];3:255. doi: 10.12688/f1000research.2644.2. eCollection 2014.

PMID:
25566350
[PubMed]
Free PMC Article
4.

[Craniocervical mass in a chronic hemodialyzed patient.]

Awada A, Wahab A, Moussa R.

Rev Neurol (Paris). 2014 Dec 30. pii: S0035-3787(14)01059-5. doi: 10.1016/j.neurol.2014.10.012. [Epub ahead of print] French. No abstract available.

PMID:
25555851
[PubMed - as supplied by publisher]
5.

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A.

Breast Cancer Res Treat. 2014 Dec;148(3):553-61. doi: 10.1007/s10549-014-3144-y. Epub 2014 Nov 8.

PMID:
25381136
[PubMed - in process]
Free PMC Article
6.

A Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early FDG PET-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.

Lalami Y, Garcia C, Flamen P, Ameye L, Paesmans M, Awada A.

Head Neck. 2014 Oct 21. doi: 10.1002/hed.23898. [Epub ahead of print]

PMID:
25332069
[PubMed - as supplied by publisher]
7.

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart M, Sotiriou C, Ignatiadis M.

Ann Oncol. 2014 Oct;25(10):1959-65. doi: 10.1093/annonc/mdu288. Epub 2014 Jul 25.

PMID:
25185240
[PubMed - in process]
8.

A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).

Fumoleau P, Koch KM, Brain E, Lokiec F, Rezai K, Awada A, Hayward L, Werutsky G, Bogaerts J, Marréaud S, Cardoso F.

Breast. 2014 Oct;23(5):663-9. doi: 10.1016/j.breast.2014.07.003. Epub 2014 Jul 24.

PMID:
25065668
[PubMed - in process]
9.

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study.

Deleporte A, Paesmans M, Garcia C, Vandeputte C, Lemort M, Engelholm JL, Hoerner F, Aftimos P, Awada A, Charette N, Machiels G, Piccart M, Flamen P, Hendlisz A.

BMC Cancer. 2014 May 30;14:385. doi: 10.1186/1471-2407-14-385.

PMID:
24885112
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.

Polastro L, Aftimos PG, Awada A.

Expert Rev Anticancer Ther. 2014 Jun;14(6):649-65. doi: 10.1586/14737140.2014.920693. Review.

PMID:
24852360
[PubMed - indexed for MEDLINE]
11.

Impact of tumor sequencing on the use of anticancer drugs.

Thomas F, Desmedt C, Aftimos P, Awada A.

Curr Opin Oncol. 2014 May;26(3):347-56. doi: 10.1097/CCO.0000000000000078. Review.

PMID:
24709974
[PubMed - indexed for MEDLINE]
12.

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

Awada A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart M; CT4002 study group.

Ann Oncol. 2014 Apr;25(4):824-31. doi: 10.1093/annonc/mdu025.

PMID:
24667715
[PubMed - indexed for MEDLINE]
13.

Anticancer drug development: moving away from the old habits.

Ades F, Zardavas D, Aftimos P, Awada A.

Curr Opin Oncol. 2014 May;26(3):334-9. doi: 10.1097/CCO.0000000000000076. No abstract available.

PMID:
24614094
[PubMed - indexed for MEDLINE]
14.

Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.

Krayem M, Journe F, Wiedig M, Morandini R, Sales F, Awada A, Ghanem G.

Eur J Cancer. 2014 May;50(7):1310-20. doi: 10.1016/j.ejca.2014.01.021. Epub 2014 Feb 19.

PMID:
24559688
[PubMed - indexed for MEDLINE]
15.

Molecular biology in medical oncology: diagnosis, prognosis, and precision medicine.

Aftimos PG, Barthelemy P, Awada A.

Discov Med. 2014 Feb;17(92):81-91. Review.

PMID:
24534471
[PubMed - indexed for MEDLINE]
Free Article
16.

Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome.

Awada A, Nicaise C, Ena S, Schandéné L, Rasschaert J, Popescu I, Gangji V, Soyfoo MS.

Ann Rheum Dis. 2014 Jun;73(6):1259-63. doi: 10.1136/annrheumdis-2012-203187. Epub 2014 Jan 2.

PMID:
24385203
[PubMed - indexed for MEDLINE]
17.

Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.

Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M, Yarden Y, Zwierzina H, Zielinski CC; Biotherapy Development Association (BDA).

Ann Oncol. 2014 Apr;25(4):773-80. doi: 10.1093/annonc/mdt531. Epub 2013 Dec 18.

PMID:
24351401
[PubMed - indexed for MEDLINE]
18.

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA; NKTR-102 Study Group.

Lancet Oncol. 2013 Nov;14(12):1216-25. doi: 10.1016/S1470-2045(13)70429-7. Epub 2013 Oct 4.

PMID:
24095299
[PubMed - indexed for MEDLINE]
19.

Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.

de Azambuja E, Zardavas D, Lemort M, Rossari J, Moulin C, Buttice A, D'Hondt V, Lebrun F, Lalami Y, Cardoso F, Sotiriou C, Gil T, Devriendt D, Paesmans M, Piccart-Gebhart M, Awada A.

Ann Oncol. 2013 Dec;24(12):2985-9. doi: 10.1093/annonc/mdt359. Epub 2013 Sep 7.

PMID:
24013582
[PubMed - indexed for MEDLINE]
Free Article
20.

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Martin M, Bonneterre J, Geyer CE Jr, Ito Y, Ro J, Lang I, Kim SB, Germa C, Vermette J, Wang K, Wang K, Awada A.

Eur J Cancer. 2013 Dec;49(18):3763-72. doi: 10.1016/j.ejca.2013.07.142. Epub 2013 Aug 15.

PMID:
23953056
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk